Supporting Information

Neuropsychiatric disease-associated dopamine transporter coding variants display heterogeneous molecular phenotypes

Freja Herborg[1], Thorvald F. Andreassen[1], Frida Berlin[1]
Claus J. Loland[1] & Ulrik Gether[1]

[1]Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, Panum Institute - Maersk Tower 07.05, University of Copenhagen, DK–2200 Copenhagen, Denmark

---



Figure S1. Evaluation of MTSET sensitivity upon alanine substitution of endogenous cysteines. Cysteine engineered construct were generated to evaluate conformational alterations within I312F, T356M, D421N, and A559V. The mutations were introduced into the MTSET insensitive background construct, E2C, in which two endogenous cysteines were substituted for alanines (C90A and C306A). MTSET-dependent inhibition of [^{3}H]-dopamine uptake was evaluated to assess if the mutations affected MTSET insensitivity of the E2C background constructs. MTSET accessibility was assessed by treating COS-7 cells, expressing the indicated cysteine engineered constructs, with vehicle or 0.5mM MTSET prior to performing [^{3}H]-dopamine uptake. MTSET is reported here as the MTSET-induced inhibition of uptake (in % of vehicle). We did not observe significant differences in MTSET sensitivity between E2C-WT DAT and the variant constructs, $p>0.05$, N=5-9, One-way ANOVA with Dunnett's post hoc test.